In a research report released today, Roth Capital analyst Scott Henry maintained coverage with a Buy rating on Synergy Pharmaceuticals (SGYP), and a $8.50 price target, following the company’s second …
Catalyst Pharmaceutical (CPRX) announced Monday that the last patient has completed the blinded portion of the ongoing pivotal phase 3 study of Firdapse (amifampridine phosphate) …
In a research note issued August 11, Roth Capital analyst Scott Henry maintained coverage with a Buy rating on Tonix Pharmaceuticals (TNXP) and a $17 price target, following the …
In a research report published August 8, Roth Capital analyst Scott Henry downgraded shares of Alexza Pharmaceuticals (ALXA) from a Buy to a Neutral rating with …
Yesterday, Roth Capital analyst Scott Henry issued a note in which he reiterated a Neutral rating on Depomed Inc. (DEPO) with a $13.
In a research note published yesterday, Roth Capital analyst Scott Henry reiterated a Buy rating on BioDelivery Sciences (BDSI) with a $16.50 price …
In a research report published yesterday, Roth Capital analyst Scott Henry maintained a Buy rating on Discovery Laboratories (DSCO) with a $5.50 price target.
In research note published yesterday, Roth Capital analyst Scott Henry reiterated a Buy rating on ANI Pharmaceuticals (ANIP) with a $40 price target, …
Friday, after the close, ANI Pharmaceuticals (ANIP) announced that the company acquired US rights to the antibiotic Vancocin (125mg and 250mg capsules) from Shire (SHPG). The …
Yesterday, Roth Capital analyst Scott Henry issued a note in which he maintained a Buy rating on ANI Pharmaceuticals (ANIP) with a $40 …
